<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156687</url>
  </required_header>
  <id_info>
    <org_study_id>14-354</org_study_id>
    <nct_id>NCT02156687</nct_id>
  </id_info>
  <brief_title>Randomized Trial of Y Mesh vs Dual Mesh</brief_title>
  <official_title>A Prospective Randomized Trial Comparing Restorelle Y Mesh vs. Restorelle Dual Flat Mesh for Laparoscopic and Robotic-assisted Laparoscopic Sacrocolpopexy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the proposed study is to determine the difference in suturing time&#xD;
      when using the restorelle Y mesh versus the restorelle dual flat mesh at the time of&#xD;
      laparoscopic and robotic-assisted laparoscopic sacrocolpopexy.&#xD;
&#xD;
      Hypothesis: Suturing time when using the restorelle Y mesh will be faster than when using the&#xD;
      restorelle dual flat mesh at the time of laparoscopic and robotic-assisted laparoscopic&#xD;
      sacrocolpopexy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design: Randomized single-blind prospective clinical trial&#xD;
&#xD;
      Primary Outcomes:&#xD;
&#xD;
        1. Total Suturing time for mesh placement = time from insertion of Y mesh or first flat&#xD;
           mesh arm into pelvis to last sacral suture placed&#xD;
&#xD;
        2. Total Case time = Incision to end of closure&#xD;
&#xD;
      Secondary Outcomes:&#xD;
&#xD;
      Post-operative patient outcomes at 24-months&#xD;
&#xD;
        -  Pelvic Floor Dysfunction Inventory (PFDI-20)&#xD;
&#xD;
        -  Pelvic Organ Prolapse Distress Inventory (POPDI)&#xD;
&#xD;
        -  Colorectal Anal Distress Inventory (CRADI)&#xD;
&#xD;
        -  Urogenital Distress Inventory (UDI)&#xD;
&#xD;
        -  Objective Recurrence (POP-Q)&#xD;
&#xD;
        -  Subjective Recurrence (vaginal bulge)&#xD;
&#xD;
        -  Reported mesh erosion&#xD;
&#xD;
      Study Population: Study subjects will be recruited from patients that present to the Center&#xD;
      of Urogynecology and Pelvic Floor Disorders in the Department of Obstetrics and Gynecology at&#xD;
      the Cleveland Clinic main campus, Hillcrest Hospital and Fairview Hospital, and their&#xD;
      surgeries will be performed at either one of these sites.&#xD;
&#xD;
      Study Procedures:&#xD;
&#xD;
      Study Identification and Recruitment Potential subjects will be identified by members of the&#xD;
      Center for Urogynecology and Pelvic Reconstructive Surgery at the Cleveland Clinic main&#xD;
      campus and Fairview Hospital. Eligible patients that agree to participate will be provided&#xD;
      written informed consent administered by the collaborators listed on this Investigational&#xD;
      Research Board (IRB) proposal at Cleveland Clinic Main campus and Fairview Hospitals.&#xD;
&#xD;
      Randomization All subjects will be predetermined by their surgeon to undergo either a&#xD;
      laparoscopic or robotic assisted laparoscopic sacrocolpopexy depending upon their clinical&#xD;
      evaluation. The participants will then be randomized to either Y mesh or dual flat mesh&#xD;
      sacrocolpopexy according to a computer-generated randomization schedule with random block&#xD;
      sizes with the use of the SAS statistical software package (SAS Institute, Cary, NC).&#xD;
      Randomization will be carried out by provider. All patients will be blinded to their&#xD;
      assignment.&#xD;
&#xD;
      Office Interventions In addition to a standardized evaluation including the history and&#xD;
      physical examination, patients will be asked to complete the Pelvic Floor Distress Inventory&#xD;
      (PFDI-20) questionnaire at the pre-operative visit as well as the 6, 12 and 24-month&#xD;
      postoperative visit. Completion of these questionnaire is the only additional assessment that&#xD;
      is specific to participation in this study and is not usually included as part of the&#xD;
      standard care of sacrocolpopexy. It should take no more than 10-15 minutes to complete the&#xD;
      questionnaire. The study subjects will not be exposed to any additional risk by participating&#xD;
      in this study except for the inconvenience of completing the questionnaire.&#xD;
&#xD;
      Surgical Interventions Laparoscopic sacrocolpopexy will be performed using four ports: an&#xD;
      umbilical port for the laparoscope, two ports (either 5 or 10/12 mm) in the bilateral lower&#xD;
      quadrants, and one 5-mm port placed at the level of the umbilicus, lateral to the rectus&#xD;
      muscle on either side for retraction. The robotic-assisted hysterectomy will be performed&#xD;
      using the da Vinci Surgical System (Intuitive Surgical Inc., Sunnyvale, CA, USA) using five&#xD;
      ports: a 12mm umbilical port for the laparoscopic, two 8 mm robotic ports placed 2cm inferior&#xD;
      and 9-10cm lateral to the umbilicus bilaterally, an 8mm robotic port placed in the left&#xD;
      axillary line at the level of the umbilicus, and a 8mm or 10/12mm accessory port either in&#xD;
      the right upper quadrant approximately 3cm distal from the costal margin, or in the right&#xD;
      lower quadrant, 2cm above and medial to the anterior superior iliac spine.&#xD;
&#xD;
      If a supracervical hysterectomy is to be performed, it will be done in a standard fashion. A&#xD;
      uterine manipulator will be placed inside of the uterus. The round ligaments will be&#xD;
      transected using cautery. The fallopian tubes and ovaries will be left in situ or removed at&#xD;
      the time of hysterectomy depending upon the preoperative decision made between the surgeon&#xD;
      and patient. The uterine arteries and cardinal ligaments will be cauterized laparoscopically.&#xD;
      The uterus will be amputated at the level of the internal cervical os and the endocervical&#xD;
      canal will be cauterized.&#xD;
&#xD;
      The sacrocolpopexy will also be performed and in a standard fashion. An end-to-end&#xD;
      anastomosis (EEA) sizer will be placed in the vagina for manipulation of the apex as well as&#xD;
      in the rectum for delineation of the rectovaginal septum. First, the presacral dissection&#xD;
      will be performed with a longitudinal peritoneal incision over the sacral promontory and&#xD;
      there is identification of the anterior longitudinal ligament. Dissection is then done&#xD;
      caudally through the peritoneum and subperitoneal fat down to the level of the posterior&#xD;
      cul-de-sac. The vagina is elevated cephalad using the EEA sizer and the peritoneum overlying&#xD;
      the anterior vaginal apex is incised transversely, and the bladder is dissected off the&#xD;
      anterior vagina using sharp dissection, creating a 4 to 5 cm pocket. If this plane is&#xD;
      difficult to establish, the bladder will be filled in a retrograde fashion to find the&#xD;
      correct dissection plane. Similarly, the peritoneum overlying the posterior vagina is&#xD;
      incised, and dissection is then done overlying the vagina and extending into the posterior&#xD;
      cul-de-sac, creating a 4 to 5 cm pocket. Once dissection is complete, the mesh graft is&#xD;
      prepared. Subjects will have been randomized to either one of two mesh grafts:&#xD;
&#xD;
        1. Restorelle Y mesh&#xD;
&#xD;
             -  The mesh is introduced into the pelvis through one of the ports.&#xD;
&#xD;
             -  First, either then anterior or the posterior arm is fixed to the anterior or&#xD;
                posterior vaginal wall using 5 delayed- absorbable (PDS) No. 2-0 sutures in an&#xD;
                interrupted fashion, 1 to 2 cm apart from each other.&#xD;
&#xD;
             -  The opposing arm of the graft is then attached to either the anterior or posterior&#xD;
                vaginal wall, depending on which arm was placed first, in a similar fashion using 5&#xD;
                delayed- absorbable (PDS) No. 2-0 sutures in an interrupted fashion, 1 to 2 cm&#xD;
                apart from each other.&#xD;
&#xD;
             -  The stem portion of the graft is then brought to the sacral promontory and sutured&#xD;
                to the anterior longitudinal ligament using 2 permanent (prolene) No. 0 sutures.&#xD;
                The excess mesh is then trimmed.&#xD;
&#xD;
        2. Restorelle dual flat mesh: 2 pieces of 15 x 4 cm mesh&#xD;
&#xD;
             -  One mesh arm is introduced into the pelvis through one of the ports.&#xD;
&#xD;
             -  The arm is fixed to the anterior or posterior vaginal wall using 5 delayed-&#xD;
                absorbable (PDS) No. 2-0 sutures in an interrupted fashion, 1 to 2 cm apart from&#xD;
                each other.&#xD;
&#xD;
             -  The second mesh arm is then introduced into the pelvis through one of the ports.&#xD;
&#xD;
             -  The arm is fixed to either the anterior or posterior vaginal wall, depending on&#xD;
                where the first arm was placed, using 5 delayed- absorbable (PDS) No. 2-0 sutures&#xD;
                in an interrupted fashion, 1 to 2 cm apart from each other.&#xD;
&#xD;
             -  The two arms are then brought to the sacral promontory and sutured together to the&#xD;
                anterior longitudinal ligament using 2 permanent (prolene) No. 0 sutures. The&#xD;
                excess mesh is then trimmed.&#xD;
&#xD;
      The peritoneum is then closed over the exposed graft with absorbable suture. Routine&#xD;
      cystoscopy will also be performed in order to assess for lower urinary tract injury. A&#xD;
      vaginal exam is performed, and an anterior and/or posterior colporrhaphy and perineorrhaphy&#xD;
      are performed if needed. Anti-incontinence procedures may also be performed if needed.&#xD;
&#xD;
      **In laparoscopic cases, all suturing will be done extracorporeally while intracorporeal&#xD;
      knot-tying technique will be performed in robot assisted laparoscopic cases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 14, 2014</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">November 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Suturing Time for Mesh Placement = Time From Insertion of Y Mesh or First Flat Mesh Arm Into Pelvis to Last Sacral Suture Placed</measure>
    <time_frame>one day intraoperative</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Total OR Time = Operating Room Time of Entry and Exit</measure>
    <time_frame>one day intraoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-operative Mean Difference POPDI at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Mean difference between baseline (pre-procedure) and 24-months post-procedure. The POPDI is a six-item measure from the PFDI-20 which measures 6 different pelvic organ prolapse symptoms and degree of bother. The scale exists from 0-100 (0=no symptoms, 100=worse symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Mean Difference CRADI at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Mean difference between baseline (pre-procedure) and 24-months post-procedure. The CRADI is a eight-item measure from the PFDI-20 which measures 8 different pelvic organ prolapse symptoms and degree of bother. The scale exists from 0-100 (0=no symptoms, 100=worse symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Mean Difference UDI at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Mean difference between baseline (pre-procedure) and 24-months post-procedure. The UDI is a six-item measure from the PFDI-20 which measures 6 different pelvic organ prolapse symptoms and degree of bother. The scale exists from 0-100 (0=no symptoms, 100=worse symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Subjective Recurrence at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Subjective Recurrence was defined as patients who complained of vaginal bulge symptoms (Question #3 on the PFDI-20).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative Objective Recurrence at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Objective Recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reported Mesh Erosion at 24 Months</measure>
    <time_frame>24 months</time_frame>
    <description>Mesh Erosion was defined as presence of eroded mesh in the vagina on examination postoperatively up to 24-months after surgery.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Prolapse</condition>
  <arm_group>
    <arm_group_label>Cololast, Inc. Restorell Y mesh</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Y mesh</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Coloplast, Inc. Restorelle Dual flat mesh</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dual flat mesh</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Y mesh</intervention_name>
    <description>Y mesh</description>
    <arm_group_label>Cololast, Inc. Restorell Y mesh</arm_group_label>
    <other_name>Cololast, Inc. Restorell Y mesh</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dual flat mesh</intervention_name>
    <description>Dual flat mesh</description>
    <arm_group_label>Coloplast, Inc. Restorelle Dual flat mesh</arm_group_label>
    <other_name>Coloplast, Inc. Restorelle Dual flat mesh</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18, who are to undergo laparoscopic or robotic laparoscopic sacrocolpopexy for&#xD;
             pelvic organ prolapse&#xD;
&#xD;
          -  Other concomitant laparoscopic or prolapse and anti-incontinence procedures (e.g.,&#xD;
             laparoscopic supracervical hysterectomy, cystocele repair, rectocele repair or&#xD;
             mid-urethral sling procedures) will be performed at the primary surgeon's discretion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to comprehend written and/or spoken English&#xD;
&#xD;
          -  Inability to provide informed consent&#xD;
&#xD;
          -  Medical illness precluding laparoscopy&#xD;
&#xD;
          -  Need for concomitant surgeries not related to pelvic organ prolapse or incontinence&#xD;
&#xD;
          -  Sacrocolpoperineopexy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cecile Unger, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <results_first_submitted>July 8, 2020</results_first_submitted>
  <results_first_submitted_qc>October 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 29, 2020</results_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02156687/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Coloplast, Inc. Restorelle Y Mesh</title>
          <description>Subjects implanted with Coloplast, Inc. Restorelle Y mesh at the time of minimally invasive sacrocolpopexy.</description>
        </group>
        <group group_id="P2">
          <title>Coloplast, Inc. Restorelle Dual Flat Mesh</title>
          <description>Subjects implanted with Coloplast, Inc. Restorelle Dual flat mesh at the time of minimally invasive sacrocolpopexy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cololast, Inc. Restorell Y Mesh</title>
          <description>Y mesh&#xD;
Y mesh: Y mesh</description>
        </group>
        <group group_id="B2">
          <title>Coloplast, Inc. Restorelle Dual Flat Mesh</title>
          <description>Dual flat mesh&#xD;
Dual flat mesh: Dual flat mesh</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="29"/>
            <count group_id="B3" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="7.3"/>
                    <measurement group_id="B2" value="62.4" spread="8.1"/>
                    <measurement group_id="B3" value="61" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.9" spread="3.5"/>
                    <measurement group_id="B2" value="28.2" spread="4.2"/>
                    <measurement group_id="B3" value="28.5" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tobacco use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Parity</title>
          <units>pregnancies</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3" lower_limit="1" upper_limit="6"/>
                    <measurement group_id="B2" value="2" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="B3" value="3" lower_limit="1" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prior prolapse surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prolapse Stage 1</title>
          <description>Patients who had Prolapse stage 1 based on POP-Q exam; this is a standardized measure. The most distal portion of the prolapse is &gt;1 cm above the level of the hymen (i.e., its quantitation value is &lt;-1 cm). Very mild prolapse - organs are still fairly well supported by the pelvic floor.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prolapse Stage 2</title>
          <description>Patients who had Prolapse stage 2 based on POP-Q exam; this is a standardized measure. The most distal portion of the prolapse is ≤1 cm proximal to or distal to the plane of the hymen (i.e., its quantitation value is ≥-1 cm but ≤+1 cm). Pelvic floor organs have begun to fall, but are still contained inside the vagina.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prolapse Stage 3</title>
          <description>Patients who had Prolapse stage 3 based on POP-Q exam; this is a standardized measure. The most distal portion of the prolapse is &gt;1 cm below the plane of the hymen but protrudes no further than 2 cm less than the total vaginal length in centimeters (i.e., its quantitation value is &gt;+1 cm but &lt;+[TVL-2] cm). Pelvic floor organs have fallen to, or beyond the opening of the vagina.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Prolapse Stage 4</title>
          <description>Patients who had Prolapse stage 4 based on POP-Q exam; this is a standardized measure. Essentially, complete eversion of the total length of the lower genital tract is demonstrated. The distal portion of the prolapse protrudes to at least (TVL-2) cm (i.e., its quantitation value is ≥+[TVL-2] cm). In most instances, the leading edge of stage IV prolapse is the cervix or vaginal cuff scar. Pelvic floor organs have fallen completely through the vaginal opening.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Suturing Time for Mesh Placement = Time From Insertion of Y Mesh or First Flat Mesh Arm Into Pelvis to Last Sacral Suture Placed</title>
        <time_frame>one day intraoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Coloplast, Inc. Restorelle Y Mesh</title>
            <description>Y mesh&#xD;
Y mesh: Y mesh</description>
          </group>
          <group group_id="O2">
            <title>Coloplast, Inc. Restorelle Dual Flat Mesh</title>
            <description>Dual flat mesh&#xD;
Dual flat mesh: Dual flat mesh</description>
          </group>
        </group_list>
        <measure>
          <title>Total Suturing Time for Mesh Placement = Time From Insertion of Y Mesh or First Flat Mesh Arm Into Pelvis to Last Sacral Suture Placed</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" spread="14.7"/>
                    <measurement group_id="O2" value="46.3" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Total OR Time = Operating Room Time of Entry and Exit</title>
        <time_frame>one day intraoperative</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Coloplast, Inc. Restorelle Y Mesh</title>
            <description>Y mesh&#xD;
Y mesh: Y mesh</description>
          </group>
          <group group_id="O2">
            <title>Coloplast, Inc. Restorelle Dual Flat Mesh</title>
            <description>Dual flat mesh&#xD;
Dual flat mesh: Dual flat mesh</description>
          </group>
        </group_list>
        <measure>
          <title>Total OR Time = Operating Room Time of Entry and Exit</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.2" spread="52.8"/>
                    <measurement group_id="O2" value="204.5" spread="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-operative Mean Difference POPDI at 24 Months</title>
        <description>Mean difference between baseline (pre-procedure) and 24-months post-procedure. The POPDI is a six-item measure from the PFDI-20 which measures 6 different pelvic organ prolapse symptoms and degree of bother. The scale exists from 0-100 (0=no symptoms, 100=worse symptoms).</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Coloplast, Inc. Restorelle Y Mesh</title>
            <description>Y mesh&#xD;
Y mesh: Y mesh</description>
          </group>
          <group group_id="O2">
            <title>Coloplast, Inc. Restorelle Dual Flat Mesh</title>
            <description>Dual flat mesh&#xD;
Dual flat mesh: Dual flat mesh</description>
          </group>
        </group_list>
        <measure>
          <title>Post-operative Mean Difference POPDI at 24 Months</title>
          <description>Mean difference between baseline (pre-procedure) and 24-months post-procedure. The POPDI is a six-item measure from the PFDI-20 which measures 6 different pelvic organ prolapse symptoms and degree of bother. The scale exists from 0-100 (0=no symptoms, 100=worse symptoms).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-32.5" spread="24.1"/>
                    <measurement group_id="O2" value="-40.7" spread="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Mean Difference CRADI at 24 Months</title>
        <description>Mean difference between baseline (pre-procedure) and 24-months post-procedure. The CRADI is a eight-item measure from the PFDI-20 which measures 8 different pelvic organ prolapse symptoms and degree of bother. The scale exists from 0-100 (0=no symptoms, 100=worse symptoms).</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Coloplast, Inc. Restorelle Y Mesh</title>
            <description>Y mesh&#xD;
Y mesh: Y mesh</description>
          </group>
          <group group_id="O2">
            <title>Coloplast, Inc. Restorelle Dual Flat Mesh</title>
            <description>Dual flat mesh&#xD;
Dual flat mesh: Dual flat mesh</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Mean Difference CRADI at 24 Months</title>
          <description>Mean difference between baseline (pre-procedure) and 24-months post-procedure. The CRADI is a eight-item measure from the PFDI-20 which measures 8 different pelvic organ prolapse symptoms and degree of bother. The scale exists from 0-100 (0=no symptoms, 100=worse symptoms).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.2" spread="20.6"/>
                    <measurement group_id="O2" value="-20.2" spread="16.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Mean Difference UDI at 24 Months</title>
        <description>Mean difference between baseline (pre-procedure) and 24-months post-procedure. The UDI is a six-item measure from the PFDI-20 which measures 6 different pelvic organ prolapse symptoms and degree of bother. The scale exists from 0-100 (0=no symptoms, 100=worse symptoms).</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Coloplast, Inc. Restorelle Y Mesh</title>
            <description>Y mesh&#xD;
Y mesh: Y mesh</description>
          </group>
          <group group_id="O2">
            <title>Coloplast, Inc. Restorelle Dual Flat Mesh</title>
            <description>Dual flat mesh&#xD;
Dual flat mesh: Dual flat mesh</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Mean Difference UDI at 24 Months</title>
          <description>Mean difference between baseline (pre-procedure) and 24-months post-procedure. The UDI is a six-item measure from the PFDI-20 which measures 6 different pelvic organ prolapse symptoms and degree of bother. The scale exists from 0-100 (0=no symptoms, 100=worse symptoms).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-39.0" spread="27.0"/>
                    <measurement group_id="O2" value="-33.2" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Subjective Recurrence at 24 Months</title>
        <description>Subjective Recurrence was defined as patients who complained of vaginal bulge symptoms (Question #3 on the PFDI-20).</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Coloplast, Inc. Restorelle Y Mesh</title>
            <description>Y mesh&#xD;
Y mesh: Y mesh</description>
          </group>
          <group group_id="O2">
            <title>Coloplast, Inc. Restorelle Dual Flat Mesh</title>
            <description>Dual flat mesh&#xD;
Dual flat mesh: Dual flat mesh</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Subjective Recurrence at 24 Months</title>
          <description>Subjective Recurrence was defined as patients who complained of vaginal bulge symptoms (Question #3 on the PFDI-20).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Objective Recurrence at 24 Months</title>
        <description>Objective Recurrence</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Coloplast, Inc. Restorelle Y Mesh</title>
            <description>Y mesh&#xD;
Y mesh: Y mesh</description>
          </group>
          <group group_id="O2">
            <title>Coloplast, Inc. Restorelle Dual Flat Mesh</title>
            <description>Dual flat mesh&#xD;
Dual flat mesh: Dual flat mesh</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Objective Recurrence at 24 Months</title>
          <description>Objective Recurrence</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reported Mesh Erosion at 24 Months</title>
        <description>Mesh Erosion was defined as presence of eroded mesh in the vagina on examination postoperatively up to 24-months after surgery.</description>
        <time_frame>24 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Coloplast, Inc. Restorelle Y Mesh</title>
            <description>Y mesh&#xD;
Y mesh: Y mesh</description>
          </group>
          <group group_id="O2">
            <title>Coloplast, Inc. Restorelle Dual Flat Mesh</title>
            <description>Dual flat mesh&#xD;
Dual flat mesh: Dual flat mesh</description>
          </group>
        </group_list>
        <measure>
          <title>Reported Mesh Erosion at 24 Months</title>
          <description>Mesh Erosion was defined as presence of eroded mesh in the vagina on examination postoperatively up to 24-months after surgery.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected up to 6 weeks after index surgery</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Coloplast, Inc. Restorelle Y Mesh</title>
          <description>Y mesh&#xD;
Y mesh: Y mesh</description>
        </group>
        <group group_id="E2">
          <title>Coloplast, Inc. Restorelle Dual Flat Mesh</title>
          <description>Dual flat mesh&#xD;
Dual flat mesh: Dual flat mesh</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The biggest limitation in this study was lost to follow-up; however, this limitation was mitigated apriori by considering potential lost to follow-up in our power analysis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Cecile Ferrando, M.D.</name_or_title>
      <organization>Cleveland Clinic</organization>
      <phone>216-444-0642</phone>
      <email>ferranc2@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

